– USA, CA – Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers, today announced the appointment of Scott Garland to its board of directors.
Mr. Garland is a 30-year veteran of the biopharmaceutical industry with deep commercial and executive leadership experience.
“We are very pleased to welcome Scott to our board of directors at this important stage in Day One’s evolution,” said CEO, Dr. Jeremy Bender. “Having led the launch of multiple new medicines, Scott’s commercial expertise will be invaluable as we advance our pivotal Phase 2 FIREFLY-1 clinical trial of DAY101 in pediatric patients with progressive low-grade glioma and prepare to initiate additional clinical trials.”
About Scott Garland
Scott Garland is CEO of PACT Pharma, an immuno-oncology company focused on developing neoantigen-targeted T-cell therapies for solid tumors. Before PACT, Mr. Garland served as president and CEO of Portola Pharmaceuticals, where he led the company through the commercial launch of Andexxa and a successful acquisition by Alexion. Before joining Portola, Mr. Garland was at Relypsa, where he served as chief commercial officer, and then as president of the U.S. organization after Relypsa’s acquisition by Vifor Pharma. Before Relypsa, Mr. Garland was the chief commercial officer at Exelixis where he led the launch of cabozantinib. Mr. Garland has held numerous other commercial leadership roles at Genentech, Amgen, and Merck, including leading the commercial franchises for two multi-billion dollar therapies – Avastin and Rituxan. He also serves as a board member for Calithera Biosciences.
“I am proud to join Day One’s board of directors and share in the Company’s mission of advancing promising new targeted cancer therapies for children and patients of all ages,” said Mr. Garland. “Day One’s product pipeline, led by DAY101, holds great potential for patients and I look forward to working with the Company’s talented board and management team to help prepare for potential commercialization.”
Mr. Garland received a Bachelor of Science degree from California Polytechnic State University-San Luis Obispo and a master’s degree in Business Administration from the Fuqua School of Business at Duke University.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genomically defined cancers. Day One was founded to address a critical unmet need: children with cancer are being left behind in a cancer drug development revolution. Our name was inspired by the “The Day One Talk”1 that physicians have with patients and their families about an initial cancer diagnosis and treatment plan. We aim to re-envision cancer drug development and redefine what’s possible for all people living with cancer—regardless of age—starting from Day One.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important emerging cancer treatments. The Company’s lead product candidate, DAY101, is an oral, highly-selective type II pan-RAF kinase inhibitor, and is being evaluated in a pivotal Phase 2 clinical trial in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma. The Company’s pipeline also includes the investigational agent pimasertib, a clinical-stage, oral, small molecule found to selectively inhibit mitogen-activated protein kinase kinases 1 and 2. Through Day One and its collaborators, cancer drug development comes of age. Day One is based in South San Francisco.
For more information: https://dayonebio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.